Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

D Fitchett, J Butler, P van de Borne… - European heart …, 2018 - academic.oup.com
Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF)
hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in …
被引用次数：273 相关文章

[引用][C] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG …

D Fitchett, OE Johansen, SSE Inzucchi… - European heart …, 2018 - difusion.ulb.ac.be
[PDF] oup.com

[PDF][PDF] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® …

D Fitchett, J Butler, P van de Borne… - European Heart …, 2018 - academic.oup.com
Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF)
hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in …

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME (R) trial

D Fitchett, J Butler, P van de Borne… - European heart …, 2018 - repository.uantwerpen.be
Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF)
hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in …
[HTML] bwise.kr

[HTML][HTML] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME …

D Fitchett, J Butler, P van de Borne… - EUROPEAN …, 2018 - scholarworks.bwise.kr
Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF)
hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in …

[引用][C] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® …

D Fitchett, J Butler, P van de Borne, B Zinman… - European Heart …, 2017 - cir.nii.ac.jp
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization
across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial | CiNii …

[引用][C] Effects of Empagliflozin on Risk for Cardiovascular Death and Heart Failure Hospitalization Across the Spectrum of Heart Failure Risk in the EMPA-REG …

D Fitchett, J Butler, P van de Borne… - European Heart …, 2017 - hsrc.himmelfarb.gwu.edu
"Effects of Empagliflozin on Risk for Cardiovascular Death and Heart Fa" by David Fitchett, Javed
Butler et al. Home Search Browse Collections My Account About DC Network Digital Commons …

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial.

D Fitchett, J Butler, P van de Borne… - European Heart …, 2018 - search.ebscohost.com
Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF)
hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in …
[PDF] archive.org

[PDF][PDF] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG …

D Fitchett, J Butler, P van de Borne… - European Heart …, 2018 - scholar.archive.org
Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF)
hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in …

Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.

D Fitchett, J Butler, P van de Borne, B Zinman… - European Heart …, 2018 - europepmc.org
Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF)
hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in …